ATCC's High Containment Facility Renovations in Support of NIAID and Pandemic Preparedness

项目总结： 拟议的项目旨在翻新ATCC位于美国 弗吉尼亚州马纳萨斯的类型培养物收藏(ATCC)。ATCC的7,500英尺2生物遏制设施 在NIAID的资助下于2007年建立，一直致力于开发传染性 快速推进诊断、疫苗和治疗所需的病株和试剂 对抗优先病原体。自2003年以来，ATCC一直与NIAID合作，集中和提供 通过生物防御和新感染资源(BEI)获得的关键科学资源 资源)计划。NIAID建立了BEI Resources来提供全球研究 具有研究A、B和C类优先级的试剂、工具和信息的社区 病原体、新出现的传染病病原体和其他与 人类健康。在过去的18年里，ATCC为超过1,360,000种试剂提供了 来自119个国家3740个机构的14,000名调查人员，涉及500多种人类病原体 在NIAID的优先投资组合中。在此期间，BEI Resources为 重大疾病爆发，包括H1N1、MERS、埃博拉和寨卡病毒。在过去的两年里，ATCC 迅速创造了690多个SARS-CoV-2产品；收购、生产和鉴定 超过165份SARS-CoV-2病毒股票，用于一般研究和挑战研究；以及 向70多个国家的2800多名研究人员运送了8.6万多种研究试剂 用于发展对策和基础研究。BEI提供的材料 自2020年2月以来，已有1800多份SARS-CoV-2出版物引用了相关资源。 此外，ATCC还促进了NIAID计划和 外部工作组共享资源、信息和数据以加速发现和 协调应对和准备大流行的科学方法。 ATCC的高密封性设施容纳了BSL-3和选择试剂所必需的实验室 传染病研究、产品开发和大规模试剂生产 研究社区。这项提案旨在改造和提升暖通空调，净化， 和安全系统。翻新还包括对固定设备和内部设施进行升级 在设施中完成。翻新将使设施现代化，供40名博士ATCC使用 科学家、合作者和实验室支持人员。中开发的产品和服务 该设施每年将支持全球数千名科学家准备和应对 大流行。ATCC正在寻找与NIAID接触的机会，以投资于 这一设施一直是该国应对和准备大流行的基础。

Project Summary: The proposed project aims to renovate ATCC's High Containment Facility (HCF) at the American Type Culture Collection (ATCC) in Manassas, Virginia. ATCC's 7,500 ft2 biocontainment facility was built in 2007 with funding from NIAID and has been dedicated to developing infectious disease strains and reagents needed to rapidly advance diagnostics, vaccines, and therapeutics against priority pathogens. Since 2003, ATCC has partnered with NIAID to centralize and provide critical scientific resources through the Biodefense and Emerging Infections Resources (BEI Resources) program. The NIAID established BEI Resources to provide the global research community with reagents, tools, and information for studying Category A, B, and C priority pathogens, emerging infectious disease agents, and other microbiological materials relevant to human health. Over the past 18 years, ATCC has provided over 1,360,000 reagents to over 14,000 investigators at 3,740 institutions in 119 countries spanning over 500 human pathogens in NIAID's priority portfolio. During this period, BEI Resources has provided critical materials for vital disease outbreaks, including H1N1, MERS, Ebola, and Zika. Over the past two years, ATCC has rapidly created more than 690 SARS-CoV-2 products; acquired, produced, and authenticated more than 165 stocks of SARS-CoV-2 for both general research and challenge studies; and shipped more than 86,000 research reagents to over 2,800 researchers in more than 70 countries for the development of countermeasures and basic research. The material provided by BEI Resources has been cited in more than 1,800 SARS-CoV-2 publications since February of 2020. In addition, ATCC has fostered collaboration and partnerships across NIAID programs and external working groups to share resources, information, and data to accelerate discoveries and harmonize scientific approaches for pandemic response and preparedness. ATCC's high containment facility houses laboratories essential for BSL-3 and Select Agent infectious disease research, product development, and large-scale reagent production for the research community. This proposal aims to renovate and upgrade the HVAC, decontamination, and security systems. The renovations also include upgrades to fixed equipment and interior finishing in the facility. The renovations will modernize the facility for use by 40 Ph.D. ATCC scientists, collaborators, and laboratory support staff. The products and services developed in the facility will support thousands of scientists globally each year to prepare and respond to pandemics. ATCC is seeking this opportunity for engagement with the NIAID to invest in this facility which has been foundational for the nation's pandemic response and preparedness.